BlackRock, Inc. 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
6,744,049 7.800% |
-2,043,601 (-23.26%) |
Filing |
| 2024-12-06 4:28 pm Purchase |
2024-11-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
8,787,650 10.300% |
548,570 (+6.66%) |
Filing |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
8,239,080 9.700% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
8,239,080 9.700% |
1,223,532 (+17.44%) |
Filing |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
7,015,548 8.300% |
2,663,516 (+61.20%) |
Filing |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
4,352,032 6.400% |
662,138 (+17.94%) |
Filing |
| 2022-02-07 4:41 pm Purchase |
2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
3,689,894 7.000% |
1,369,488 (+59.02%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
2,320,406 5.000% |
492,980 (+26.98%) |
Filing |
| 2020-09-09 3:52 pm Purchase |
2020-08-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BlackRock Inc. BLK |
1,827,426 4.700% |
112,945 (+6.59%) |
Filing |